Putney Financial Group LLC Invests $385,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Putney Financial Group LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 955 shares of the pharmaceutical company's stock, valued at approximately $385,000.

Other large investors have also recently made changes to their positions in the company. Brown Lisle Cummings Inc. acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $30,000. Golden State Wealth Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $37,000. Truvestments Capital LLC grew its holdings in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after purchasing an additional 23 shares during the period. Mpwm Advisory Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $40,000. Finally, Midwest Capital Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $41,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VRTX shares. Leerink Partnrs lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Barclays increased their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. increased their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $515.04.

Insider Activity

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded down $5.36 during trading on Friday, hitting $441.73. 499,365 shares of the company were exchanged, compared to its average volume of 1,633,158. The company has a market cap of $113.44 billion, a price-to-earnings ratio of -200.78, a PEG ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The firm's fifty day moving average price is $470.99 and its 200 day moving average price is $461.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.76 earnings per share. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.